Breakers of advanced glycation end products restore large artery properties in experimental diabetes. - Wikidata - wikimedia - TriplyDB

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

http://www.wikidata.org/entity/Q36477705

about

The role of collagen crosslinks in ageing and diabetes - the good, the bad, and the ugly Simple non-invasive assessment of advanced glycation endproduct accumulation Advanced glycation: an important pathological event in diabetic and age related ocular disease Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)Pimagedine: a novel therapy for diabetic nephropathy.[Vessel aging. The role of oxidative stress and protein glycation].Localized micro- and nano-scale remodelling in the diabetic aorta.Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis.Early lens aging is accelerated in subjects with a high risk of ischemic heart disease: an epidemiologic study.Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage.Thioredoxin glycation: A novel posttranslational modification that inhibits its antioxidant and organ protective actions Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity.ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure.Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice.The maillard reaction in eye diseases.Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain.Clinical applications of arterial stiffness: therapeutics and pharmacology.A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys Caloric restriction mimetics: metabolic interventions.Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults.Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats.An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.Involvement of Maillard reactions in Alzheimer disease.Medical treatment of diabetic retinopathy.Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness.Age-related vascular stiffening: causes and consequences.Regulation of RAGE for attenuating progression of diabetic vascular complications.Novel therapeutic strategies for reducing arterial stiffness Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats.Coronary arterioles in type 2 diabetic (db/db) mice undergo a distinct pattern of remodeling associated with decreased vessel stiffness.Emerging drugs for renal failure.Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy Impact of experimental diabetes on the maternal uterine vascular remodeling during rat pregnancy.Agents in development for the treatment of diabetic nephropathy.

P2860

Q26864529-9560750C-2333-4E95-B85C-0CEFE45FB5ED Q28271097-85A21582-6938-43F0-B70E-6AD5825CD4A7 Q28365776-078788D3-071B-4B7F-9D97-35AC75FF3170 Q28366662-0C66B959-0D2F-4420-AF89-1C925D49CAFE Q30309168-8C20EF8A-6EA5-4A66-8ABA-FD0FBC2C7AC6 Q30318375-C0A42C7D-D34D-414B-B22E-5879B7B46F6F Q30426876-24CBD659-56FB-475B-B006-0914BD8F2EDE Q31146191-E56B7235-B1BB-405E-95B9-1E11C7A46676 Q32107919-455AD858-0D8E-450D-A591-358CE0FECCF6 Q33240082-C9ACDC15-9CA9-462A-B114-0F7A8A793585 Q33609776-79A101F1-2548-4B60-A1B4-4EBFFFCB5C4E Q33623472-FEEF2A76-DE57-4055-8085-63ACDD813271 Q33976920-0F7715B5-D75F-45A8-A8B1-CA17BECDCBE6 Q34085212-DC1F5EB4-0C77-4F69-8B43-E6DB72483160 Q34292699-29A7A200-0B60-4B4E-8E5A-C0F05A1A54A4 Q34399952-A2AA3B7B-BE34-46C9-94EA-45A82302AFC2 Q34436018-F7DB9737-4E4A-44D2-8CCA-18D7DBCCC48C Q34481838-981DBCA8-9830-4124-B8CA-38B4A4EA9C7E Q34557662-3B4D0195-F83E-46B2-B5D1-214C25286405 Q34647819-63DF351A-7F57-4C48-A208-687F8B80D947 Q34652366-49236E6B-4578-4A1C-AAE1-4C36EDB1D1D2 Q34712074-3A175142-A603-404F-96F6-CAACD80A4FC5 Q34885399-3C1FF293-A1BC-4723-8E4F-8659FA055521 Q35047489-54C484BD-E904-4841-9D7F-522EDF6D21D6 Q35081898-B67367C2-1F7A-41D3-95AC-FCB813C29D89 Q35164047-CB74B8C3-D661-47CE-8435-B76273CE1F54 Q35175679-55480D41-63C6-4BAB-A6B9-BCAA518EE5F2 Q35177586-8B6A4952-BDF0-4139-9199-1BFD01125D72 Q35409645-BE01731B-535D-46E2-BDCE-008EDB87108A Q35494903-D7C49737-F525-4771-A78B-AFD4A9DC71C9 Q35546271-A8B50739-CD55-4AB9-BC07-2221C3F14486 Q35566544-130C3FE6-1337-4DC5-8C74-B82A5E54C34C Q35589548-4CF580FA-8208-4DBD-9CEE-D114D619BA1A Q35602657-43654C5F-6735-49B0-B704-00EF5B114732 Q35766899-3DFE08EC-A6D2-40E1-BD9F-5F50138812B2 Q35796793-A54811E5-816F-4B41-89F2-D38FC8B7CA6C Q35809946-4A73889A-ABB3-403C-83C2-6017C9768AA3 Q35887541-6BDE7C2F-829A-4A12-844B-36CF1D924518 Q35931171-8879255B-1C6A-40A3-9EBC-ADBB9DBDB0AF Q36099419-E24A78D2-D002-4B2A-B705-D5288E90D85A

P2860

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

http://www.wikidata.org/entity/Q36477705

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Breakers of advanced glycation ...... ties in experimental diabetes.

@ast

Breakers of advanced glycation ...... ties in experimental diabetes.

@en

type

label

Breakers of advanced glycation ...... ties in experimental diabetes.

@ast

Breakers of advanced glycation ...... ties in experimental diabetes.

@en

prefLabel

Breakers of advanced glycation ...... ties in experimental diabetes.

@ast

Breakers of advanced glycation ...... ties in experimental diabetes.

@en

P1433

Q36477705-F61864DB-0378-42C1-A0F4-77001D9C9A6D

P1476

Q36477705-255BA4EE-584D-4F61-AA1D-097E7DD7A814

P2093

Q36477705-3AD46517-76FB-4750-BF70-5B3AE1129CDE

Q36477705-5B5C46E4-0EF8-42C8-929C-5F87E33B41BB

Q36477705-87E51FF7-5F5E-4DB1-81D1-B37AE53493EA

Q36477705-8E5A7378-5331-4C62-B561-1B911AD11683

Q36477705-A5FB699D-E2F9-4865-8C32-9FF28A1F5296

Q36477705-BAAE2EC6-0D67-47FD-B226-2249B429B170

Q36477705-CAD15519-E284-4A67-B7B7-7328CEF5B17A

Q36477705-E00FA7FE-F737-4221-8697-3A17BE74D42E

Q36477705-F9DCE067-8031-4A67-905D-806FB330255E

P2860

Q36477705-0BCBF5E2-CD8E-47F1-B58C-38B2B68C25B7

Q36477705-0D20F25E-0274-46DA-B6E5-71008B14375E

Q36477705-224C3681-02FC-4CE0-B11A-508F4FB44786

Q36477705-4BD943E4-0A3C-426A-B2A6-2187230EE0DE

Q36477705-663920C1-76C3-483E-A0E7-56621C39482E

Q36477705-78F428CC-23CE-4086-9AEB-3A63B20D7F1E

Q36477705-A570D3CA-7819-46C2-BA84-1910B4C7F2D3

Q36477705-B414C9E5-DC1E-42E0-82BA-3708F98D2049

Q36477705-B8DCADAD-5B60-4F6B-8026-27FFABC32A04

Q36477705-CD42A5CA-35D4-4F9E-906A-64E6416AD5B0

P304

Q36477705-8D29462F-4556-4C3C-BABF-93997AB9EC6F

P31

Q36477705-33BDFF85-EEE5-4BC5-A95B-C937D3973DE3

P356

Q36477705-1A8CDC93-7589-4CBA-BD9D-921EF30F9EE9

P407

Q36477705-3E993DE5-FEEB-4CD1-93A5-595D8F094676

P433

Q36477705-BCEF0D45-2881-46D6-9111-4130B7ED1C9C

P478

Q36477705-7AFBF039-4651-4C07-A66B-BAF8FD930C64

P50

Q36477705-2ECD4EC0-CA16-4251-ABFA-2E07CBE0D71D

Q36477705-4AB25955-3159-42A9-8C4E-0B93CB389C11

P577

Q36477705-6A5BD3EA-A984-4DC6-AAE3-FE988068C4A8

P5875

Q36477705-1837C3D0-2E5D-4082-B43D-7D503E535DC1

P698

Q36477705-77F7F556-D87A-4132-AD34-56D8A9249367

P932

Q36477705-701AF901-4090-4E1C-BAF6-E185BCDAD4AE

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Breakers of advanced glycation ...... rties in experimental diabetes

@en

P2093

A Cerami

http://www.w3.org/2001/XMLSchema#string

B I Lévy

http://www.w3.org/2001/XMLSchema#string

F R Crijns

http://www.w3.org/2001/XMLSchema#string

G N Swennen

http://www.w3.org/2001/XMLSchema#string

J J Egan

http://www.w3.org/2001/XMLSchema#string

M S Huijberts

http://www.w3.org/2001/XMLSchema#string

P Poitevin

http://www.w3.org/2001/XMLSchema#string

P Ulrich

http://www.w3.org/2001/XMLSchema#string

S Vasan

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Lilly Lecture 1993. Glycation and diabetic complications.

Biochemical alterations in collagen IV induced by in vitro glycation.

Systemic arterial compliance in normotensive and hypertensive rats.

Control of carotid vasomotor tone by local renin-angiotensin system in normotensive and spontaneously hypertensive rats. Role of endothelium and flow.

Dynamic non-invasive measurements of arterial diameter and wall thickness.

P304

4630-4634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.8.4630

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Chantal M Boulanger

Bruce H Wolffenbuttel

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51331736

http://www.w3.org/2001/XMLSchema#string

P698

9539789

http://www.w3.org/2001/XMLSchema#string

P932

22541

http://www.w3.org/2001/XMLSchema#string